文献速递临床生化临床微生物分子诊断

质谱技术在检验医学中的进展:自动化、多重生物标志物定量与诊断

Mass spectrometry in laboratory medicine: advances in automation, multiplex biomarker quantification, and diagnostics.
PubMed 文献 · Clin Chim Acta · 2026-06-01

本文综述质谱技术在检验医学中的现实转化,涵盖LC-MS/MS、MALDI-TOF MS、GC-MS等平台在微生物鉴定、单克隆蛋白分析、类固醇与治疗药物监测、新生儿筛查等应用。全自动MALDI-TOF MS平台对单克隆免疫球蛋白检测与常规电泳一致率达92.6-95.7%,多重LC-MS/MS可同时定量23种类固醇和15种蛋白结合尿毒症毒素,MassARRAY基因分型在新生儿原发性肉碱缺乏症筛查中检测成功率99.75%。

要点

  • 全自动MALDI-TOF MS对低浓度M蛋白灵敏度优于常规电泳,一致率92.6-95.7%。
  • 多重LC-MS/MS可同时定量23种血浆类固醇和15种蛋白结合尿毒症毒素。
  • MassARRAY基因分型在新生儿原发性肉碱缺乏症筛查中检测成功率99.75%。

核心结论

  • 质谱在检验医学中的近期最强适用场景为高通量、经过充分验证的用途,而非无限制替代免疫分析。
  • 自动化需结合严格分析验证、室间质量评估和明确临床效用证明,才能维持临床质谱的长期价值。

研究设计与样本

  • 综述聚焦质谱从专业参考实验室向常规临床实践的现实转化。
  • 汇总质谱测量基本原理、当前临床平台、MALDI-TOF MS微生物鉴定、自动化单克隆蛋白分析、LC-MS/MS类固醇与治疗药物监测、GC-MS应用、MassARRAY基因分型、分析前脆弱性及实施障碍。

主要发现

  • 全自动MALDI-TOF MS平台(如EXENT)对单克隆免疫球蛋白检测与常规电泳一致率达92.6-95.7%,对低浓度M蛋白灵敏度更优。
  • 多重LC-MS/MS面板可同时定量23种血浆类固醇和15种蛋白结合尿毒症毒素,线性和精密度优良。
  • 基于MassARRAY的基因分型在新生儿原发性肉碱缺乏症筛查中检测成功率达99.75%。

关键数值与推荐

  • 全自动MALDI-TOF MS平台对单克隆免疫球蛋白检测与常规电泳一致率为92.6-95.7%。
  • 多重LC-MS/MS面板可同时定量23种血浆类固醇和15种蛋白结合尿毒症毒素。
  • MassARRAY基因分型在新生儿原发性肉碱缺乏症筛查中检测成功率为99.75%。

临床怎么用

  • 近期优先在新生儿筛查、治疗药物监测、类固醇谱分析、毒理学、微生物鉴定、单克隆蛋白检测和选定的多重生物标志物面板中应用质谱。
  • 实施质谱时需配套分析验证、室间质量评估和临床效用证据。

局限性

  • 实验室间协调不完善。
  • 资本和维护成本高。
  • 需要培训人员。
  • 存在基质效应和分析前不稳定性。
  • 部分生物标志物面板证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mass spectrometry (MS) has evolved from a specialized research tool into an increasingly indispensable platform in laboratory medicine. Its clinical value is driven by molecular specificity, multiplex quantification, and the ability to measure small molecules, peptides, proteins, drugs, metabolites, and microbial spectral fingerprints in workflows that are becoming more automated and standardized. The field is nevertheless heterogeneous: liquid chromatography-tandem mass spectrometry (LC-MS/MS), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), gas chromatography-mass spectrometry (GC-MS), and emerging high-resolution or miniature instruments address different clinical questions and require different validation strategies. The review focuses on the realistic transition of MS from specialist reference laboratories to routine clinical practice. It summarizes fundamental principles of MS measurement, current clinical platforms, microbial identification by MALDI-TOF MS, automated monoclonal protein analysis, LC-MS/MS steroid and therapeutic drug monitoring, GC-MS applications, MassARRAY genotyping, pre-analytical vulnerabilities, and barriers to implementation. Fully automated MALDI-TOF MS platforms (e.g., EXENT) now achieve 92.6-95.7% concordance with conventional electrophoresis for monoclonal immunoglobulin detection while showing superior sensitivity for low-concentration M-proteins. Multiplex LC-MS/MS panels enable simultaneous quantification of 23 plasma steroids and 15 protein-bound uremic toxins with excellent linearity and precision, whereas MassARRAY-based genotyping has achieved 99.75% detection success in newborn screening for primary carnitine deficiency. Critical remaining limitations include incomplete inter-laboratory harmonization, high capital and maintenance costs, the need for trained personnel, matrix effects, pre-analytical instability, limited evidence for some biomarker panels, and uncertain regulatory pathways for laboratory-developed tests. The strongest near-term applicability is expected in high-volume, well-validated use cases - newborn screening, therapeutic drug monitoring, steroid profiling, toxicology, microbial identification, monoclonal protein testing, and selected multiplex biomarker panels - rather than unrestricted replacement of immunoassays. The future relevance of clinical MS is likely to remain strong, provided that automation is coupled with rigorous analytical validation, external quality assessment, and clear demonstration of clinical utility.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Khamidova F, Tatykayeva U, Reymnazarova G, et al. Mass spectrometry in laboratory medicine: advances in automation, multiplex biomarker quantification, and diagnostics. Clin Chim Acta. 2026. PMID: 42229708. doi:10.1016/j.cca.2026.121128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。